β-blockers: a novel class of antitumor agents

@inproceedings{Ji2012blockersAN,
  title={β-blockers: a novel class of antitumor agents},
  author={Yi Ji and Siyuan Chen and Xianmin Xiao and Shan Zheng and Kai Li},
  booktitle={OncoTargets and therapy},
  year={2012}
}
β-adrenergic signaling modulates key signaling pathways that are important for tumor-promoting processes, and numerous mechanisms of action have been elucidated. Preclinical studies have demonstrated that β-adrenergic antagonists, or β-blockers, can block multiple fundamental biologic processes underlying the progression and metastasis of tumors, including the inhibition of cell proliferation, migration, invasion, resistance to programmed cell death, and tumor angiogenesis and metastasis. Human… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation

  • American journal of hematology
  • 2016
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives

  • Journal of Cancer Research and Clinical Oncology
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

Opioids and cancer recurrence.

  • Current opinion in supportive and palliative care
  • 2014

Signaling pathways in the development of infantile hemangioma

  • Journal of Hematology & Oncology
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 129 REFERENCES

Molecular pathways: beta-adrenergic signaling in cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…